Below is a press release dated May 7, 2026 from ACR:
New research using death certificate data from 52,942 females, reveals that systemic lupus erythematosus (lupus) is a leading cause of years of potential life lost among young women in the United States, underscoring the disease’s significant and often underrecognized public health burden.
The study, titled “Lupus, a leading cause of years of potential life lost in young women: implications for public health priorities and research funding,” published in ACR Open Rheumatology, finds that lupus disproportionately affects women during their most productive years, contributing to premature mortality and long-term societal impact.
Years of potential life lost (YPLL) is a key public health metric that measures premature death. The study shows that lupus ranks among the top causes of YPLL in young women. This study adds to the authors’ previous work that showed that lupus is among the leading causes of death —particularly among Black, Hispanic, and other historically underserved populations—highlighting persistent health disparities.
“These findings reinforce what the rheumatology community has long observed: lupus is not only a chronic disease but a life-threatening condition that cuts lives short,” said lead researcher Ram Raj Singh, M.D. at the David Geffen School of Medicine at the University of California at Los Angeles (UCLA). “Despite this, it remains underfunded relative to its impact.”
Key findings from the study include:
- Lupus is a leading contributor to premature mortality among women of reproductive age.
- The societal and economic costs of lupus are amplified by its impact during peak working and caregiving years.
The authors emphasize that the findings should prompt policymakers and research agencies to re-evaluate funding priorities. Despite its high burden, lupus research funding has historically lagged behind other diseases with comparable or lower YPLL.
Advocates say the study strengthens the case for:
- Increased federal investment in lupus research through agencies such as the National Institutes of Health (NIH).
- Expanded access to early diagnosis and specialized care.
- Development of safe, effective, and affordable treatments for lupus.
- Public health initiatives aimed at reducing disparities and improving outcomes in high-risk populations.
“Addressing lupus requires a coordinated national strategy,” said Andras Perl, MD, PhD, Editor-in-Chief of ACR Open Rheumatology. “We have an opportunity to save lives by investing in research, improving access to care, and raising awareness of this devastating disease.”
Lupus is a chronic autoimmune disease in which the immune system attacks healthy tissues, leading to inflammation and damage across multiple organ systems. There is currently no cure.